Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: Analysis of immunological parameters

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 861-868

  Ohwada, Susumu ^a,b   Ogawa, Tetsushi ^a   Makita, Fujio ^a   Tanahashi, Yoshifumi ^a   Ohya, Toshihiro ^a   Tomizawa, Naoki ^a   Satoh, Yoshihiro ^a   Kobayashi, Isao ^a   Izumi, Masaru ^a   Takeyoshi, Izumi ^a   Hamada, Kunihiro ^a   Minaguchi, Shigeyuki ^a   Togo, Yasushi ^a   Toshihiko, Tago ^a   Koyama, Toru ^a   Kamio, Masashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Immunosuppressive acidic protein; Polysaccharide K; Tegafur uracil

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; IMMUNOSUPPRESSIVE ACID PROTEIN; KRESTIN; PROTEOGLYCAN; PS-K; TEGAFUR; TUMOR PROTEIN; URACIL;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIGENS, CD11B; ANTIGENS, CD57; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEOGLYCANS; RECEPTORS, IGG; RISK FACTORS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 33746404839     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.861     Document Type: Article

References (33)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 870-873, 1999.
2. Stevenson HC, Green I, Hamilton JM, Calabro BA and Parkinson DR: Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 9: 2052-2066, 1991.
3. Grem JL and Allegra CJ: Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst 81: 1413-1417, 1989. (Pubitemid 19224199)
4. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990. (Pubitemid 20042739)
5. IMPACT: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: 939-944, 1995.
6. Vermorken JB, Claessen AM, van Tinteren H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353: 345-350, 1999. (Pubitemid 29088160)
7. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
8. Hirose K, Zachariae CO, Oppenheim JJ and Matsushima K: Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 9: 475-483, 1990. (Pubitemid 20384838)
9. Ebina T and Murata K: Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Jpn J Cancer Res 83: 775-782, 1992.
10. Kato M, Hirose K, Hakozaki M, et al: Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 40: 152-156, 1995.
11. Yefenof E, Gafanovitch I, Oron E, Bar M and Klein E: Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 41: 389-396, 1995. (Pubitemid 26045108)
12. Kobayashi H, Matsunaga K and Oguchi Y: Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 4: 275-281, 1995.
13. Algarra I, Collado A and Garrido F: Protein-bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res 16: 373-380, 1997. (Pubitemid 28083536)
14. +T-cell response in gut-associated lymphoid tissue (GALT) of specific pathogen-free mice. Int J Cancer 70: 362-372, 1997.
15. Pedrinaci S, Algarra I and Garrido F: Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res 29: 135-140, 1999.
16. Ohwada S, Ikeya T, Yokomori T, et al: Adjuvant immunochemotherapy with oral tegafur/uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 90: 1003-1010, 2004. (Pubitemid 38495819)
17. Mitomi T, Tsuchiya S, Iijima N, et al: Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130, 1992.
18. Fisher M and Yang LX: Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22: 1737-1754, 2002. (Pubitemid 34839190)
19. Yefenof E, Einat E and Klein E: Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 34: 133-137, 1991.
20. Nio Y, Tsubono M, Tseng CC, et al: Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy 4: 117-128, 1992.
21. Tamura K, Shibata Y, Matsuda Y and Ishida N: Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 41: 3244-3252, 1981. (Pubitemid 11035548)
22. Zhang H, Morisaki T, Nakahara C, et al: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22: 2088-2096, 2003. (Pubitemid 36539559)
23. Garcia-Lora A, Martinez M, Pedrinaci S and Garrido F: Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother 52: 59-64, 2003. (Pubitemid 36181530)
24. Aboud M, Kingsmore S and Segal S: Role of natural killer cells in controlling local tumor formation and metastatic manifestation of different 3LL Lewis lung carcinoma cell clones. Nat Immun 12: 17-24, 1993. (Pubitemid 23079736)
25. Mori H, Mihara M, Teshima K, et al: Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. Int J Immunopharmacol 9: 881-892, 1987. (Pubitemid 17165121)
26. Iwaguchi T, Shimizu M and Hayashi H: Analysis of electrophoretic mobility histograms of mouse splenocytes and thymocytes during tumor growth and after combined chemotherapy and immunotherapy. J Biochem Biophys Methods 18: 157-166, 1989. (Pubitemid 19102186)
27. Iino Y, Takai Y, Sugamata N and Morishita Y: PSK (Krestin) potentiates chemotherapeutic effects of tamoxifen on rat mammary carcinomas. Anticancer Res 12: 2101-2103, 1992. (Pubitemid 23105413)
28. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651, 2001. (Pubitemid 34292600)
29. Zhang H, Morisaki T, Matsunaga H, et al: Protein-bound polysaccharide PSK inhibits tumor invasiveness by downregulation of TGF-beta1 and MMPs. Clin Exp Metastasis 18: 343-352, 2000. (Pubitemid 32579404)
30. Sakamoto J, Teramukai S, Koike A, Saji S, Ohashi Y and Nakazato H: Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer 77: 2206-2212, 1996. (Pubitemid 26162410)
31. Toge T and Yamaguchi Y: Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 7: 1157-1161, 2000.
32. Ogoshi K, Miyaji M, Nakamura K, Kondoh Y, Makuuchi H and Tajima T: Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants. Cancer Immunol Immunother 46: 14-20, 1998. (Pubitemid 28133400)
33. Ogoshi K, Tajima T, Mitomi T, Makuuchi H and Tsuji K: HLA-A2 Antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother 45: 53-59, 1997. (Pubitemid 27444470)